Marshall Wace North America’s Takeda Pharmaceutical TAK Stock Holding History

Marshall Wace North America’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-336,601	Closed	-$5.67M	–	1706
2021 Q2	$5.67M	Buy	336,601 +224,602	+201%	+$3.82M	0.02%	520
2021 Q1	$2.04M	Buy	111,999 +41,196	+58%	+$741K	0.01%	820
2020 Q4	$1.29M	Sell	70,803 -663,207	-90%	-$11.6M	0.01%	878
2020 Q3	$13.1M	Buy	734,010 +264,213	+56%	+$4.81M	0.08%	240
2020 Q2	$8.42M	Buy	+469,797	New	+$8.43M	0.06%	283
2020 Q1	–	Sell	-370,993	Closed	-$7.32M	–	1587
2019 Q4	$7.32M	Sell	370,993 -141,816	-28%	-$2.71M	0.04%	334
2019 Q3	$8.82M	Buy	+512,809	New	+$8.87M	0.05%	278

Other funds holding TAK

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Marshall Wace North America's TAK Position: Q3 2021 in Review

Marshall Wace North America sold out of Takeda Pharmaceutical (TAK) in Q3 2021, closing a stake of 336,601 shares — an estimated $5.67M sold.

Marshall Wace North America first reported a position in TAK in Q3 2019 and held it in 7 quarters. The position peaked at $13.1M in Q3 2020. 293 funds tracked by Wall St. Rank hold TAK as of Q3 2021.

Marshall Wace North America reported no remaining Takeda Pharmaceutical position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 336,601 Takeda Pharmaceutical shares in Q3 2021, an estimated $5.67M.
Marshall Wace North America first reported a position in Takeda Pharmaceutical in Q3 2019 and held it in 7 quarters.
Marshall Wace North America's Takeda Pharmaceutical position peaked at $13.1M in Q3 2020.
293 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.